3 Boomerang Capital has announced a majority growth investment in Enjoin.
Enjoin, founded in 1988 and based in Collierville, Tennessee, provides clinical documentation integrity solutions for hospitals and health systems.
3 Boomerang, based in Greenwich, Conn., invests in lower middle market healthcare companies in North America and Western Europe. Founded in 2023, the…
Valeas Capital Partners has announced the closing of its first institutional fund at more than $600 million.
The inaugural fund, VCP Fund I, exceeded its target.
Valeas, founded in 2021 and based in San Francisco, is a middle-market, growth-buyout private equity firm. The firm prefers to invest between $50 million and $150 million in companies…
A recent decision by a federal court in the Eastern District of New York illustrates how directors and officers (“D&O”) policies can provide valuable insurance coverage for defense costs and potential liabilities arising from False Claims Act (“FCA”) litigation. In Northern Metropolitan Foundation for Healthcare, Inc. v. RSUI Indemnity Company, Case No. 20-CV-2224 (EK)…
Argosy Healthcare Partners (AHP) has announced the recapitalization of Nicklas Medical Staffing (NMS).
NMS, founded in 2013 and based in Jacksonville, Florida, provides staffing solutions for pathology and histology labs.
AHP, based in Wayne, Pennsylvania, is a lower middle market private equity investor focused exclusively on healthcare. A division of Argosy Capital, AHP…
By Kevin Madagan
Ampersand Capital Partners has announced its acquisition of Nektar Therapeutics’ PEGylation reagent manufacturing business.
The business, which will be branded Gannet BioChem and continue to operate out of its facility in Huntsville, Alabama, develops, scales and manufactures polyethylene glycol (PEG) reagents, which are used in advanced biopharmaceutical and therapeutic products.
On December 3, 2024, the United States District Court for the Eastern District of Texas issued a nationwide preliminary injunction against enforcement of the Corporate Transparency Act (“CTA”). Enacted as part of the Anti-Money Laundering Act of 2020, the CTA requires certain legal entities to report beneficial ownership information (“BOI”) to the U.S. Department of…
Frazier Healthcare Partners has announced the closing of a new fund with $2.3 billion of commitments.
The fund, Frazier Healthcare Growth Buyout Fund XI, was oversubscribed and hit its hard cap in six months. The fund will focus on acquiring controlling interests in middle-market healthcare companies.
Frazier, based in Seattle, is a provider of…
As 2024 comes to a close, companies created prior to January 1, 2024 should be mindful of the year-end deadline to analyze whether they must report Beneficial Ownership Information (“BOI”) to the U.S. Department of Treasury’s Financial Crimes Enforcement Network (“FinCEN”) pursuant to the reporting provisions of the Corporate Transparency Act (“CTA”). Companies should take immediate action to determine whether filing is necessary to avoid potential civil and/or criminal penalties. McGuireWoods described the CTA’s requirements in a previous post and the requirements are also summarized below.
As the pharma services sector grows, regulators at the Department of Justice and Food and Drug Administration are putting everything from clinical trials to site management under the microscope.
McGuireWoods partner Clint Narver speaks from experience: He joined the firm after serving in leadership roles at both agencies. With host Geoff Cockrell, Clint helps…
Notable litigation filed in October 2024 includes: (1) Jolley v. WCM Global Wealth, LLC, et al., No. 2024CP2306268 (S.C. Com. Pl.); (2) Vazquez, et al., v. Inventis Ventures Holding, Inc., et al., No. 2024-01436108 (Cal. Super. Ct.); and (3) Jaramillo v. AM Transport Group LLC, et al., No. 2024-020463-CA-01 (Fla. Cir. Ct.).…
